Drug Profile


Alternative Names: Aldenon; Aldenonc; IY-81149; Noltec; Yi Li An

Latest Information Update: 07 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Il-Yang
  • Developer Il-Yang; Livzon Group; Takeda
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 27 Feb 2018 Il-Yang Pharm plans a phase III trial for Gastro oesophageal reflux, in April 2018 (PO) (NCT03444883)
  • 01 Jan 2017 Il-Yang Pharm completes a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT02998437)
  • 01 Dec 2016 Il-Yang Pharm initiates a phase I drug-drug interaction trial in Healthy volunteers in South Korea (PO) (NCT02998437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top